



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

1. Name of Inspector from whom received : Mr. R. Vanlalruata, Assistant Director (F and D)
ASSISTANT DIRECTOR (F&D)
OFFICE OF CHIEF MEDICAL OFFICER, AIZAWL,
MIZORAM, PIN-769017
2. Serial No. and date of Inspector's memorandum : MZ/2025/CMO E/IPA/9, 20-JAN-2025
3. Number of Sample : NIL
4. Date of receipt : 29-JAN-2025
5. Names of drugs purporting to be contained in the sample : Telmisartan and Hydrochlorothiazide Tablets IP
(Tellme- 80H)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-26/0298	GUW/LS/2025-26/310	TA-24042	Jan-2024 Dec-2025	NA	Horizon Bioceuticals Pvt. Ltd., Plot No. 3 & 3A, Industrial Area, Trilokpur Road, Kala Amb, Distt. Sirmour (HP) -173030.

6. Condition of seals on : Seals were intact & identical to the
[the packet or on portion of sample or container] specimen impression of the seal received
from Drugs Inspector

7. Result of test or analysis with protocols or test or analysis applied : Please see below

Date of Testing : From 28-Mar-2025 To 28-May-2025

COMPOSITION : Each uncoated tablet contains: Telmisartan IP 80 mg Hydrochlorothiazide IP
12.5 mg

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	Bi-layered (orange colored and white),elongated, biconvex, uncoated tablets, in blister pack.	NA
2	Identification	Gives positive test for Telmisartan and Hydrochlorothiazide.	NA
3	Average weight	0.5935 g	NA
4	Uniformity of weight	Complies.	+5 % of Average weight
5	Dissolution (for Telmisartan)	Complies.	NLT 80 % of claim
6	Dissolution (For Hydrochlorothiazide)	Complies.	NLT 80 % of claim

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Telmisartan	83.76 mg/Tablet	80 mg/Tablet	104.7	95 % to 105 %	I.P. 2022
2	Hydrochlorothiazide	11.82 mg/Tablet	12.5 mg/Tablet	94.56	90 % to 107.5 %	I.P. 2022

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Date: 29-MAY-2025


GOVERNMENT ANALYST

 **Rinku Kalita**
Government Analyst
R.D.T.L., Guwahati-22

-----END OF REPORT-----